当前位置: X-MOL 学术Clin. Gastroenterol. Hepatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Mucosal Healing With Vedolizumab in Patients With Chronic Pouchitis: EARNEST, a Randomized, Double-Blind, Placebo-Controlled Trial
Clinical Gastroenterology and Hepatology ( IF 11.6 ) Pub Date : 2024-07-16 , DOI: 10.1016/j.cgh.2024.06.037
Vipul Jairath 1 , Brian G Feagan 2 , Mark S Silverberg 3 , Silvio Danese 4 , Paolo Gionchetti 5 , Mark Löwenberg 6 , Brian Bressler 7 , Marc Ferrante 8 , Ailsa Hart 9 , Dirk Lindner 10 , Armella Escher 10 , Stephen Jones 11 , Bo Shen 12 , Simon Travis 13
Affiliation  

Vedolizumab is indicated for the treatment of chronic pouchitis in the European Union. We assessed whether vedolizumab induced mucosal healing (MH) and if MH was associated with clinical improvements.

中文翻译:


维多珠单抗治疗慢性贮袋炎患者的粘膜愈合:EARNEST,一项随机、双盲、安慰剂对照试验



Vedolizumab 在欧盟用于治疗慢性贮袋炎。我们评估了维多珠单抗是否诱导粘膜愈合 (mucosal healing, MH) 以及 MH 是否与临床改善相关。
更新日期:2024-07-16
down
wechat
bug